The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease - PubMed (original) (raw)
The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease
Patrick Lefebvre et al. Dis Manag. 2007 Feb.
Abstract
The aim of this study was to evaluate the impact of epoetin alfa (EPO) therapy on delaying progression to renal dialysis and quantify the associated medical cost savings in elderly chronic kidney disease (CKD) patients. Elderly (>/=65 years) dialysis patients who had >/=1 hemoglobin (Hb) value and >/=1 glomerular filtration rate (GFR) value of <60 mL/min/1.73 m(2) were identified using health claims and laboratory data from the period January 1999 to February 2005. Exclusion criteria included: organ transplantation, blood transfusion, use of darbepoetin alfa, and dialysis for reasons other than CKD. Each EPO patient was matched by Hb and GFR to one control patient. The time from when matched patients had the same GFR value to dialysis was compared. The economic impact of EPO on delaying dialysis was monetized using standardized health plan payments, and adjusted to 2005 United States dollars. Sixty-eight patients (34 EPO and 34 matched controls) formed the study population. The average time to dialysis was 156 days longer for the EPO group compared to the matched control group (p = 0.003). Analysis by CKD severity revealed that EPO therapy in less severe CKD patients offered a greater delay in time to dialysis (Stage 4: 213 days difference, p = 0.003; Stage 5: 104 days difference, p = 0.160). EPO treatment resulted in cost savings of 43,374−43,374-43,374−59,222 per patient compared to non-EPO matched controls. This retrospective matched cohort study suggests that EPO therapy has a beneficial impact on delaying progression to dialysis in elderly CKD patients, especially in those with less severe CKD.
Similar articles
- Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C. Duh MS, et al. Clin Ther. 2006 Sep;28(9):1443-50. doi: 10.1016/j.clinthera.2006.09.020. Clin Ther. 2006. PMID: 17062316 - Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA. Winkelmayer WC, et al. Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2. Am J Kidney Dis. 2015. PMID: 25943715 Free PMC article. - Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Duh MS, et al. Drugs Aging. 2006;23(12):969-76. doi: 10.2165/00002512-200623120-00004. Drugs Aging. 2006. PMID: 17154661 - Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER, Winkelmayer WC. Wilhelm-Leen ER, et al. Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28. Am J Kidney Dis. 2015. PMID: 25636816 Free PMC article. Review. - Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C. Hymes J, et al. Curr Med Res Opin. 2007 Aug;23(8):1931-7. doi: 10.1185/030079907X210705. Curr Med Res Opin. 2007. PMID: 17624232 Review.
Cited by
- Microdissection of Primary Renal Tissue Segments and Incorporation with Novel Scaffold-free Construct Technology.
Arbra CA, Nadig SN, Dennis SG, Pattanaik S, Bainbridge HA, Rhett JM, Fann SA, Atkinson C, Yost MJ. Arbra CA, et al. J Vis Exp. 2018 Mar 27;(133):57358. doi: 10.3791/57358. J Vis Exp. 2018. PMID: 29658916 Free PMC article. - A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.
Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriguez L, Agodoa I, Mayne T. Menzin J, et al. Pharmacoeconomics. 2011 Oct;29(10):839-61. doi: 10.2165/11588390-000000000-00000. Pharmacoeconomics. 2011. PMID: 21671688 Review. - The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.
Lea JP, Norris K, Agodoa L. Lea JP, et al. Am J Nephrol. 2008;28(5):732-43. doi: 10.1159/000127981. Epub 2008 Apr 24. Am J Nephrol. 2008. PMID: 18434712 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials